Characterization of Adherence and Persistence Profile in a Real-Life Population of Patients Treated with Adalimumab.

AimsPublished data on long‐term adherence and persistence with adalimumab (Humira®) in clinical practice are scarce and often limited to selected patient populations. This study assessed adherence with adalimumab across different indications and identified correlates and outcomes of poor adherence.MethodsWe analysed data originating from the electronic database of Maccabi Healthcare Services (MHS) that includes 2.1 million enrolees. We randomly selected patients with at least one dispense of adalimumab since it was included in the local health basket in Israel in 2008 until the end of 2013. Patients with the following indications (n = 1339) were included: Crohn's disease (CD), ulcerative colitis (UC), rheumatoid arthritis (RA), psoriatic arthritis (PSA), ankylosing spondylitis (AS) and psoriasis. Adherence with therapy was assessed by the medication possession ratio (MPR) during the follow‐up period.ResultsGood adherence (MPR ≥ 80%) was observed among 80% of study patients and was associated with lower risk for ≥1 hospitalization per year of follow‐up (adjusted‐OR = 1.94, 95% CI:1.15–3.28). Patients with AS and CD persisted on adalimumab therapy the most, reaching median use of 27.0 and 26.7 months, respectively. Half (52.4%) of the patients discontinued treatment during a mean (SD) follow‐up of 3.07 (1.71) years. High socioeconomic status was associated with lower risk for discontinuation (adjusted‐HR = 0.74; 0.60–0.91). UC and concomitant prednisolone use were associated with increased risk for treatment discontinuation (HR = 1.31; 1.00–1.72, and HR = 1.40; 1.17–1.68, respectively).ConclusionOur results indicate encouraging persistence and adherence with adalimumab of patients with inflammatory conditions.